Compare with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES BIOCON ALKEM LABORATORIES/
BIOCON
 
P/E (TTM) x - 30.5 - View Chart
P/BV x 10.2 3.9 258.9% View Chart
Dividend Yield % 0.4 0.3 170.2%  

Financials

 ALKEM LABORATORIES   BIOCON
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
BIOCON
Mar-19
ALKEM LABORATORIES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,589707 224.7%   
Low Rs1,232554 222.5%   
Sales per share (Unadj.) Rs417.591.9 454.2%  
Earnings per share (Unadj.) Rs56.316.7 336.9%  
Cash flow per share (Unadj.) Rs64.724.2 267.7%  
Dividends per share (Unadj.) Rs12.701.00 1,270.0%  
Dividend yield (eoy) %0.90.2 567.7%  
Book value per share (Unadj.) Rs292.9101.6 288.2%  
Shares outstanding (eoy) m119.57600.00 19.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.46.9 49.2%   
Avg P/E ratio x25.137.7 66.4%  
P/CF ratio (eoy) x21.826.1 83.6%  
Price / Book Value ratio x4.86.2 77.6%  
Dividend payout %22.66.0 377.0%   
Avg Mkt Cap Rs m168,653378,330 44.6%   
No. of employees `000NA6.1 0.0%   
Total wages/salary Rs m9,17111,653 78.7%   
Avg. sales/employee Rs ThNM8,994.3-  
Avg. wages/employee Rs ThNM1,900.7-  
Avg. net profit/employee Rs ThNM1,635.3-  
INCOME DATA
Net Sales Rs m49,91555,144 90.5%  
Other income Rs m1,6451,444 113.9%   
Total revenues Rs m51,56156,588 91.1%   
Gross profit Rs m8,48215,883 53.4%  
Depreciation Rs m1,0064,478 22.5%   
Interest Rs m671709 94.6%   
Profit before tax Rs m8,45112,140 69.6%   
Minority Interest Rs m-1149 -1,264.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6062,123 75.6%   
Profit after tax Rs m6,73110,026 67.1%  
Gross profit margin %17.028.8 59.0%  
Effective tax rate %19.017.5 108.7%   
Net profit margin %13.518.2 74.2%  
BALANCE SHEET DATA
Current assets Rs m27,06248,228 56.1%   
Current liabilities Rs m15,32430,376 50.4%   
Net working cap to sales %23.532.4 72.6%  
Current ratio x1.81.6 111.2%  
Inventory Days Days6768 97.4%  
Debtors Days Days4186 48.3%  
Net fixed assets Rs m12,61064,130 19.7%   
Share capital Rs m2393,000 8.0%   
"Free" reserves Rs m34,49057,980 59.5%   
Net worth Rs m35,02760,980 57.4%   
Long term debt Rs m1,21215,766 7.7%   
Total assets Rs m54,387121,924 44.6%  
Interest coverage x13.618.1 75.1%   
Debt to equity ratio x00.3 13.4%  
Sales to assets ratio x0.90.5 202.9%   
Return on assets %13.68.8 154.6%  
Return on equity %19.216.4 116.9%  
Return on capital %24.916.8 148.4%  
Exports to sales %12.928.1 46.0%   
Imports to sales %3.118.9 16.4%   
Exports (fob) Rs m6,46115,506 41.7%   
Imports (cif) Rs m1,54010,399 14.8%   
Fx inflow Rs m6,56315,506 42.3%   
Fx outflow Rs m3,01210,399 29.0%   
Net fx Rs m3,5525,107 69.5%   
CASH FLOW
From Operations Rs m7,25911,546 62.9%  
From Investments Rs m1,864-7,138 -26.1%  
From Financial Activity Rs m-9,273-2,417 383.6%  
Net Cashflow Rs m-1502,103 -7.1%  

Share Holding

Indian Promoters % 66.9 40.4 165.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 33.1 8.4 394.0%  
FIIs % 0.0 10.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 19.9 -  
Shareholders   68,381 109,995 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DISHMAN PHARMA  CADILA HEALTHCARE  SUVEN LIFESCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Aug 7, 2020 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS